S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
The single greatest medical breakthrough of all time? (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
The single greatest medical breakthrough of all time? (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
The single greatest medical breakthrough of all time? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
The single greatest medical breakthrough of all time? (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
The single greatest medical breakthrough of all time? (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
The single greatest medical breakthrough of all time? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
The single greatest medical breakthrough of all time? (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
The single greatest medical breakthrough of all time? (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
The single greatest medical breakthrough of all time? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
The single greatest medical breakthrough of all time? (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
Even at $2,000+ Per Share, These 3 Stocks Are Deals
The single greatest medical breakthrough of all time? (Ad)
Will NIO Partake In China's Economic Awakening?
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
The single greatest medical breakthrough of all time? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Tax Software Specialist Vertex In Buy Zone After Base Breakout
NASDAQ:SAGE

Sage Therapeutics (SAGE) Stock Forecast, Price & News

$59.54
+2.84 (+5.01%)
(As of 06/9/2023 ET)
Compare
Today's Range
$56.46
$59.68
50-Day Range
$40.65
$59.54
52-Week Range
$30.67
$59.68
Volume
999,484 shs
Average Volume
407,608 shs
Market Capitalization
$3.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.54

Sage Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
13.4% Downside
$51.54 Price Target
Short Interest
Bearish
10.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.43
Upright™ Environmental Score
News Sentiment
1.11mentions of Sage Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$50,500 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($8.04) to ($8.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.38 out of 5 stars

Medical Sector

945th out of 988 stocks

Pharmaceutical Preparations Industry

461st out of 477 stocks


SAGE stock logo

About Sage Therapeutics (NASDAQ:SAGE) Stock

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SAGE Stock News Headlines

RBC Capital Sticks to Their Buy Rating for SAGE Therapeutics (SAGE)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
15 Most Suicidal States in America
Sage Therapeutics (NASDAQ:SAGE) PT Raised to $61.00
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
See More Headlines

SAGE Price History

SAGE Company Calendar

Last Earnings
5/02/2023
Today
6/09/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAGE
Employees
471
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$51.54
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
-13.4%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
11 Analysts

Profitability

Net Income
$-532,780,000.00
Net Margins
-5,932.09%
Pretax Margin
-5,932.09%

Debt

Sales & Book Value

Annual Sales
$7.69 million
Book Value
$21.05 per share

Miscellaneous

Free Float
56,893,000
Market Cap
$3.56 billion
Optionable
Optionable
Beta
1.15

Key Executives

  • Barry E. GreeneBarry E. Greene
    President, Chief Executive Officer & Director
  • Kimi E. Iguchi
    Chief Financial & Accounting Officer
  • Al Robichaud
    Chief Scientific Officer
  • Amy Schacterle
    Senior VP-Research & Development Strategy
  • Matt Lasmanis
    Chief Technology & Innovation Officer













SAGE Stock - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings
or view top-rated stocks.

What is Sage Therapeutics' stock price forecast for 2023?

11 brokers have issued 1-year price targets for Sage Therapeutics' shares. Their SAGE share price forecasts range from $40.00 to $70.00. On average, they anticipate the company's share price to reach $51.54 in the next twelve months. This suggests that the stock has a possible downside of 13.4%.
View analysts price targets for SAGE
or view top-rated stocks among Wall Street analysts.

How have SAGE shares performed in 2023?

Sage Therapeutics' stock was trading at $38.14 at the beginning of the year. Since then, SAGE stock has increased by 56.1% and is now trading at $59.54.
View the best growth stocks for 2023 here
.

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our SAGE earnings forecast
.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its quarterly earnings data on Tuesday, May, 2nd. The biopharmaceutical company reported ($2.46) EPS for the quarter, topping analysts' consensus estimates of ($2.50) by $0.04. The biopharmaceutical company earned $3.30 million during the quarter, compared to analysts' expectations of $2.28 million. Sage Therapeutics had a negative net margin of 5,932.09% and a negative trailing twelve-month return on equity of 42.32%. The company's revenue for the quarter was up 120.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.07) earnings per share.

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (11.85%), Wellington Management Group LLP (9.56%), BlackRock Inc. (8.25%), State Street Corp (4.58%), Price T Rowe Associates Inc. MD (3.19%) and Dimensional Fund Advisors LP (2.77%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends
.

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sage Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $59.54.

How much money does Sage Therapeutics make?

Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $3.56 billion and generates $7.69 million in revenue each year. The biopharmaceutical company earns $-532,780,000.00 in net income (profit) each year or ($9.37) on an earnings per share basis.

How many employees does Sage Therapeutics have?

The company employs 471 workers across the globe.

How can I contact Sage Therapeutics?

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379.

This page (NASDAQ:SAGE) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -